Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.
Age ≥50 years, any gender.
The study eye must have active treatment-naïve macular neovascularization (MNV) secondary to AMD, confirmed by the investigator based on OCT images showing the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) involving the fovea.
The study eye must have a best-corrected visual acuity (BCVA) measured using the 4-meter ETDRS chart of 24-78 ETDRS letters (approximately Snellen equivalent 20/320 - 20/32).
Central subfield thickness (CST) ≥300 μm.
Patients with ocular or periocular infection.
Patients with active intraocular inflammation.
Known hypersensitivity to faricimab or any of its excipients.
Previous treatment with any other investigational therapy or any therapy that affects choroidal neovascularization (CNV) or macular neovascularization (MNV), or any therapy used for AMD.
The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.
Cohort
Prospective
Not listed
Choroidal Vascularity Index (CVI)
CVI represents the proportion of the total choroidal area occupied by blood vessels (luminal area).
visual contrast sensitivity
Visual contrast sensitivity is the ability to detect differences in luminance (brightness) between an object and its background.
Height of pigment epithelial detachment
The vertical distance between the detached retinal pigment epithelium (RPE) and the underlying Bruch's membrane.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
